Pulmatrix, Inc. (PULM)
PULM Stock Price Chart
Explore Pulmatrix, Inc. interactive price chart. Choose custom timeframes to analyze PULM price movements and trends.
PULM Company Profile
Discover essential business fundamentals and corporate details for Pulmatrix, Inc. (PULM) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
21 Mar 2014
Employees
2.00
Website
https://www.pulmatrix.comCEO
Peter Ludlum
Description
Pulmatrix, Inc. (PULM) is a clinical-stage biotechnology firm focused on creating and advancing inhaled treatments. The company's primary goal is to address significant unmet medical needs in respiratory and other diseases within the United States. Central to their approach is the innovative iSPERSE (inhaled small particles easily respirable and emitted) technology. This proprietary platform allows for the precise delivery of both small and large molecule therapeutics directly into the lungs, achieving either localized effects or systemic distribution throughout the body. Pulmatrix's development pipeline includes several key candidates: Pulmazole: An inhaled antifungal drug being developed to treat allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis. PUR1800: A narrow spectrum kinase inhibitor currently undergoing Phase 1b clinical trials for individuals suffering from stable moderate-to-severe chronic obstructive pulmonary disease (COPD). PUR3100: An iSPERSE-formulated version of dihydroergotamine, intended for the rapid relief of acute migraine attacks. The company also maintains strategic collaborations, including a licensing arrangement with RespiVert Ltd. for access to a range of kinase inhibitor drug candidates, a partnership with Cipla Technologies LLC for the development and commercialization of Pulmazole, and a collaboration and license agreement with Sensory Cloud, Inc. Established in 2003, Pulmatrix, Inc. is headquartered in Lexington, Massachusetts.
PULM Financial Timeline
Browse a chronological timeline of Pulmatrix, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 Aug 2026
Earnings released on 15 May 2026
EPS came in at -$0.32 .
Earnings released on 26 Feb 2026
EPS came in at -$0.25 .
Earnings released on 16 Oct 2025
EPS came in at -$0.24 .
Earnings released on 6 Aug 2025
EPS came in at -$0.42 .
Earnings released on 15 May 2025
EPS came in at -$0.50 .
Earnings released on 21 Mar 2025
EPS came in at -$0.54 , while revenue for the quarter reached $3.00k .
Earnings released on 8 Nov 2024
EPS came in at -$0.71 , while revenue for the quarter reached $366.00k .
Earnings released on 13 Aug 2024
EPS came in at -$0.87 , while revenue for the quarter reached $1.55m , missing expectations by -29.52%.
Earnings released on 10 May 2024
EPS came in at $0.23 , while revenue for the quarter reached $5.89m , beating expectations by +167.26%.
Earnings released on 28 Mar 2024
EPS came in at -$0.57 surpassing the estimated -$1.04 by +45.19%, while revenue for the quarter reached $2.20m , beating expectations by +24.41%.
Earnings released on 9 Nov 2023
EPS came in at -$1.03 surpassing the estimated -$1.05 by +1.90%, while revenue for the quarter reached $1.75m , missing expectations by -0.96%.
Earnings released on 10 Aug 2023
EPS came in at -$1.04 surpassing the estimated -$1.23 by +15.45%, while revenue for the quarter reached $1.84m , beating expectations by +21.80%.
Earnings released on 12 May 2023
EPS came in at -$1.22 , while revenue for the quarter reached $1.50m .
Earnings released on 30 Mar 2023
EPS came in at -$1.14 surpassing the estimated -$1.44 by +20.83%, while revenue for the quarter reached $1.71m , missing expectations by -8.66%.
Earnings released on 10 Nov 2022
EPS came in at -$1.45 surpassing the estimated -$1.51 by +3.97%, while revenue for the quarter reached $1.87m , beating expectations by +61.38%.
Earnings released on 8 Aug 2022
EPS came in at -$1.36 surpassing the estimated -$1.51 by +9.93%, while revenue for the quarter reached $1.33m , beating expectations by +14.74%.
Earnings released on 12 May 2022
EPS came in at -$1.51 falling short of the estimated -$1.41 by -7.09%, while revenue for the quarter reached $1.16m , beating expectations by +8.51%.
Earnings released on 29 Mar 2022
EPS came in at -$2.43 falling short of the estimated -$1.60 by -51.88%, while revenue for the quarter reached $456.00k , missing expectations by -61.22%.
Stock split effective on 1 Mar 2022
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 10 Nov 2021
EPS came in at -$1.80 falling short of the estimated -$1.40 by -28.57%, while revenue for the quarter reached $1.07m , beating expectations by +40.00%.
Earnings released on 10 Aug 2021
EPS came in at -$1.40 surpassing the estimated -$1.80 by +22.22%, while revenue for the quarter reached $2.25m , missing expectations by -18.18%.
PULM Stock Performance
Access detailed PULM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
